PET Detection of CCR2 in Human Atherosclerosis

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT04537403
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Carotid Atherosclerosis

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Accepted

Interventions

  • Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine) — DRUG
    Patients in Group 1, normal volunteers and patients with carotid and femoral artery disease who will be having surgery, will have a 1 day imaging session lasting approximately 60 minutes with an injection of 64CU-DOTA-ECL1i to visualize the carotid and femoral arteries. Patients with carotid and femoral artery disease will have their plaque specimens collected for further sutdy
  • Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine) — DRUG
    Patients in Group 2, who are patients with carotid and femoral artery disease who will not be having surgery will have two imaging sessions 7-14 days apart

Study Details

: Use of novel radio-pharmaceutical 64CUDOTA-ECL1i to evaluate arterial atherosclrosis

Key Dates

Start date
Oct 1, 2020
Status verified
Jul 2025
Primary completion
Sep 1, 2025
Completion
Sep 1, 2025

Study Design

Enrollment
100 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: Aim 1A
    Normal volunteers and patients with Carotid and Femoral Atherosclerosis who will be having surgery
  • Experimental: Aim 1B
    Patients with Carotid and Femoral Atherosclerosis who will be managed medically and not having surgery

Primary Outcome Measure

Evaluation of 64CU-ECL1i , imaging characteristics [ Time Frame: 1 or 2 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Washington University CCIRSt LouisMissouri63110
Molly Mohrman

Find similar trials in St Louis, MO

By research site
Washington University CCIR· St Louis, MO

Related Studies